ArticleCell stem cell2017
TLRgeting Evasion of Immune Pathways in Glioblastoma.
Article in Cell stem cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Design of a novel multiepitope vaccine against glioblastoma by in silico approaches.Scientific reports · 2025Article
- Neurosteroids in Glioma: A Novel Therapeutic Concept.Life (Basel, Switzerland) · 2024Review
- Inhibition of PRMT1 Suppresses the Growth of U87MG-Derived Glioblastoma Stem Cells by Blocking the STAT3 Signaling Pathway.International journal of molecular sciences · 2024Article
- Advances in synthetic lethality modalities for glioblastoma multiforme.Open medicine (Warsaw, Poland) · 2024Review
- Review
- Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells.Molecules (Basel, Switzerland) · 2022Article
- Discovery of a New CaMKII-Targeted Synthetic Lethal Therapy against Glioblastoma Stem-like Cells.Cancers · 2022Article
- Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.Journal of hematology & oncology · 2021Review
- The Glioblastoma Microenvironment: Morphology, Metabolism, and Molecular Signature of Glial Dynamics to Discover Metabolic Rewiring Sequence.International journal of molecular sciences · 2021Review
- Article
- SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells.EMBO molecular medicine · 2020Article
- Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma.Nature communications · 2020Article
- TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.International journal of molecular sciences · 2020Review
- PamInvestigational new drugs · 2020Article
- Bidirectional Relation Between Parkinson's Disease and Glioblastoma Multiforme.Frontiers in neurology · 2020Review
- TLR-4/Wnt modulation as new therapeutic strategy in the treatment of glioblastomas.Oncotarget · 2018Article
- Roles of toll-like receptors: From inflammation to lung cancer progression.Biomedical reports · 2018Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is an intractable brain cancer that presents a strongly immunosuppressive microenvironment. Alvarado et al. (2016) now report that GBM cancer stem cells (CSCs) downregulate Toll-like receptor (TLR) 4 to evade immune suppression, and that activating downstream TLR signaling pathways can reduce tumor growth and disrupt CSC self-renewal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.